Excellent
Mostly Aligned
Patient Risk:
Low
Summary
All substantive claims made in the provided text (suicidality risk/monitoring, boxed warning content applicability, and not approved in pediatrics; plus counseling about monitoring early and with dose changes) are supported by the supplied FDA label excerpts with no direct contradictions identified.
Category Scores
Accurate Statements
Suicidal thoughts and behaviors risk is increased with antidepressants in pediatric and young adult patients; RALDESY requires close monitoring.
Boxed Warning (increased risk in pediatric and young adult patients; closely monitor) and Section 5.1 (monitor all antidepressant-treated patients; consider changing/discontinuing if emergent suicidal thoughts/behaviors).
RALDESY is not approved for use in pediatric patients.
Boxed Warning (not approved for use in pediatric patients) and Section 8.4 (safety and effectiveness not established; antidepressants increased risk; not approved in pediatrics).
Patients and caregivers should monitor for suicidality, especially early during treatment and when dosage is adjusted.
Section 5.1 (counsel family/caregivers to monitor; especially during initial few months and at times of dosage changes) and Section 17 (monitor especially early and when dosage adjusted up or down).
Unsupported Statements
Contradictions
Important Omissions
No additional label details were requested or provided beyond the suicidality/pediatric risk items; therefore no material omissions can be assessed relative to a specific question beyond those topics.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims concern boxed warning/pediatric risk and counseling/monitoring instructions that are consistent with the supplied label excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
No clear label gaps in the evaluated claims; minor scoring reduction reflects limited scope (only boxed warning/pediatric counseling sections were evaluated).
Suggested Improvement
If additional label sections are to be assessed, include explicit claims for only those sections and ensure each is directly tied to the corresponding label excerpt.